Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial
Sean Wasserman, Angharad Davis, Cari Stek, Maxwell Chirehwa, Stephani Botha, Remy Daroowala, Marise Bremer, Mpumi Maxebengula, Sonya Koekemoer, René Goliath, Amanda Jackson, Thomas Crede, Jonathan Naudé, Patryk Szymanski, Yakoob Vallie, Muhammed Shiraz Moosa, Lubbe Wiesner, John Black, Graeme Meintjes, Gary Maartens, Robert J. Wilkinson
Abstract
Higher doses of intravenous rifampicin may improve outcomes in tuberculous meningitis but are impractical in high-burden settings. We hypothesized that plasma rifampicin exposures would be similar between oral dosing of 35 mg/kg of body weight and intravenous dosing of 20 mg/kg, which has been proposed for efficacy trials in tuberculous meningitis.
Topics & Concepts
MedicineRifampicinPharmacokineticsDosingTuberculous meningitisInterquartile rangeConfidence intervalMeningitisRandomized controlled trialInternal medicineGastroenterologyPharmacologySurgeryTuberculosisPathologyInfectious Diseases and TuberculosisPneumocystis jirovecii pneumonia detection and treatmentTuberculosis Research and Epidemiology